FM
AVDL

Frazier Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Frazier Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-951,814
Closed -$7.69M – 8
2021
Q4 		$7.69M Hold
951,814
– – 0.59% 35
2021
Q3 		$9.33M Buy
951,814
+373,710
+65% +$2.94M 0.75% 28
2021
Q2 		$3.89M Hold
578,104
– – 0.36% 31
2021
Q1 		$5.23M Buy
+578,104
New +$4.67M 0.42% 28

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Frazier Management's AVDL Position: Q1 2022 in Review

Frazier Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2022, closing a stake of 951,814 shares — an estimated $7.69M sold.

Frazier Management first reported a position in AVDL in Q1 2021 and held it in 4 quarters. The position peaked at $9.33M in Q3 2021. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2022.

  • Frazier Management reported no remaining Avadel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 951,814 Avadel Pharmaceuticals shares in Q1 2022, an estimated $7.69M.
  • Frazier Management first reported a position in Avadel Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Frazier Management's Avadel Pharmaceuticals position peaked at $9.33M in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.